Trial intelligence / Profile preview

Convalescent Plasma for COVID-19

NCT04649879Phase 3Completed

Start
Dec 2020
Primary completion
Jan 2022
Modality
Recombinant Proteins and Enzymes
Countries
1
01

Overview

A Phase 3 trial of COVID-19 convalescent plasma in coronavirus disease 2019 (COVID-19). Started Dec 2020; status: completed.

02

Drugs

COVID-19 convalescent plasma
03

Conditions

coronavirus disease 2019 (COVID-19)

Beyond the preview

Go deeper on NCT04649879.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT04649879.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call